ClinicalTrials.gg
CompletedNCT00730275Updated May 12, 2017Results posted

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)

A Phase 1 interventional study of Sitagliptin phosphate and Comparator: matching placebo in Type 2 Diabetes, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
147th of 197
35 · median 102
Started
2008
with 22 others
Phase 1
23 of 198
none open now
Registered
51st of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 147th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 23 in phase 1, and was the 51st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability and pharmacokinetics of sitagliptin in 10 to 17 year old diabetic patients.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females who are 10 - 17 years of age
  • History of type 2 diabetes
  • Nonsmoker
  • No clinical or laboratory evidence to indicate a diagnosis of type 1 diabetes

Exclusion criteria

Exclusion Criteria:

  • History of diabetic ketoacidosis
  • History of stroke, chronic seizures or major neurological disorder
  • Consumes alcohol
  • Consume more than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola or other beverages containing caffeine per day
  • Unable to swallow tablets
  • Has had surgery, donated or lost 1 unit of blood, or participated in another study within a minimum of 4 weeks prior to starting the study
  • History of multiple and/or severe allergies or has had an allergic reaction to or significant intolerability to prescription or non-prescription drugs or food
  • Currently a regular user of any illicit drugs or has a history of drug or alcohol abuse
  • History of endocrine, gastrointestinal,

cardiovascular, hematological, hepatic, immunological, renal, respiratory, or

genitourinary abnormalities or diseases

  • Has an estimated of less than or equal to 80 mL/min
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Sitagliptin 50 mg

    Participants were randomized to sitagliptin 50 mg

    Drug: Sitagliptin phosphate

  • Experimental
    Sitagliptin 100 mg

    Participants were randomized to sitagliptin 100 mg

    Drug: Sitagliptin phosphate

  • Experimental
    Sitagliptin 200 mg

    Participants were randomized to a single dose of sitagliptin 200 mg

    Drug: Sitagliptin phosphate

  • Placebo comparator
    Placebo to sitagliptin

    Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg

    Drug: Comparator: matching placebo

Interventions

  • Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.

    Also known as: MK-0431, Januvia

  • DrugComparator: matching placebo

    Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced at Least One Adverse Event

    Time frame: Pre-study through 10 to 14 days following administration of study drug

  2. Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin

    Serum samples were used to determine the AUC from time 0 to infinity for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.

    Time frame: Pre-dose through 72 hours post-dose

Secondary outcomes

  1. Maximum Concentration (Cmax) Following a Single Dose of Sitagliptin

    Serum samples were used to determine the Cmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.

    Time frame: Pre-dose through 72 hours post-dose

  2. Time of Occurence of Maximum Concentration (Tmax) Following a Single Dose of Sitagliptin

    Serum samples were used to determine the Tmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.

    Time frame: Pre-dose through 72 hours post-dose

  3. Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin

    Serum samples were used to determine the apparent t1/2 for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.

    Time frame: Pre-dose through 72 hours post-dose

  4. Plasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo

    Plasma DPP-4 activity was analyzed using the 24-hour weighted average inhibition (WAI) and percent inhibition at 24 hours post-dose. WAI was defined as the AUC of inhibition divided by the length of the post-dose time interval. Positive values of WAI represent a decrease in DPP-4 activity.

    Time frame: Pre-dose through 24 hours post-dose

07

Results

Posted Jan 30, 2012

Participant flow

Participant flow — Overall Study
MilestoneSitagliptin 50 mgSitagliptin 100 mgSitagliptin 200 mgPlacebo
Started9989
Completed9988
Not completed0001
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryNumber of Participants Who Experienced at Least One Adverse Event
Time frame:
Pre-study through 10 to 14 days following administration of study drug
Reported as:
Number · participants
Number of Participants Who Experienced at Least One Adverse Event
participantsSitagliptin 50 mgSitagliptin 100 mgSitagliptin 200 mgPlacebo
Number of Participants Who Experienced at Least One Adverse Event3112
PrimaryArea Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin

Serum samples were used to determine the AUC from time 0 to infinity for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.

Time frame:
Pre-dose through 72 hours post-dose
Reported as:
Geometric mean · nM*hour
Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin
nM*hourSitagliptin 50 mgSitagliptin 100 mgSitagliptin 200 mg
Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity Following a Single Dose of Sitagliptin3438 (2881 to 4103)5869 (4918 to 7003)12965 (10749 to 15638)
SecondaryMaximum Concentration (Cmax) Following a Single Dose of Sitagliptin

Serum samples were used to determine the Cmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.

Time frame:
Pre-dose through 72 hours post-dose
Reported as:
Geometric mean · nM
Maximum Concentration (Cmax) Following a Single Dose of Sitagliptin
nMSitagliptin 50 mgSitagliptin 100 mgSitagliptin 200 mg
Maximum Concentration (Cmax) Following a Single Dose of Sitagliptin366 (288 to 464)666 (526 to 845)1876 (1458 to 2413)
SecondaryTime of Occurence of Maximum Concentration (Tmax) Following a Single Dose of Sitagliptin

Serum samples were used to determine the Tmax for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.

Time frame:
Pre-dose through 72 hours post-dose
Reported as:
Median · hours
Time of Occurence of Maximum Concentration (Tmax) Following a Single Dose of Sitagliptin
hoursSitagliptin 50 mgSitagliptin 100 mgSitagliptin 200 mg
Time of Occurence of Maximum Concentration (Tmax) Following a Single Dose of Sitagliptin3.0 (1.5 to 5.0)3.0 (2.0 to 4.5)2.5 (1.0 to 3.1)
SecondaryApparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin

Serum samples were used to determine the apparent t1/2 for sitagliptin. The placebo group is not included in the table below; this outcome measure only evaluated the sitagliptin groups.

Time frame:
Pre-dose through 72 hours post-dose
Reported as:
Mean · hours
Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin
hoursSitagliptin 50 mgSitagliptin 100 mgSitagliptin 200 mg
Apparent Terminal Half-life (Apparent t1/2) Following a Single Dose of Sitagliptin12.1 ± 1.711.2 ± 2.111.7 ± 1.8
SecondaryPlasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo

Plasma DPP-4 activity was analyzed using the 24-hour weighted average inhibition (WAI) and percent inhibition at 24 hours post-dose. WAI was defined as the AUC of inhibition divided by the length of the post-dose time interval. Positive values of WAI represent a decrease in DPP-4 activity.

Time frame:
Pre-dose through 24 hours post-dose
Reported as:
Least squares mean · Percent inhibition
Plasma Dipeptidyl Peptidase-4 (DPP-4) Activity Following a Single Dose of Sitagliptin or Placebo
Percent inhibitionSitagliptin 50 mgSitagliptin 100 mgSitagliptin 200 mgPlacebo
24-hour WAI of DPP-4 activity73.98 (70.59 to 76.99)80.53 (77.98 to 82.78)87.96 (86.29 to 89.43)6.76 (-6.21 to 18.14)
DDP-4 activity at 24 hours post-dose53.98 (46.74 to 60.24)62.78 (56.92 to 67.84)75.76 (71.70 to 79.24)3.57 (-12.60 to 17.43)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 50 mg—0/9 (0%)3/9 (33.3%)
Sitagliptin 100 mg—0/9 (0%)1/9 (11.1%)
Sitagliptin 200 mg—0/8 (0%)1/8 (12.5%)
Placebo—0/9 (0%)2/9 (22.2%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventSitagliptin 50 mgSitagliptin 100 mgSitagliptin 200 mgPlacebo
VomitingGastrointestinal disorders0/90/91/80/9
AnaemiaBlood and lymphatic system disorders0/90/90/81/9
Abdominal painGastrointestinal disorders1/90/90/80/9
Abdominal pain upperGastrointestinal disorders1/90/90/80/9
DiarrhoeaGastrointestinal disorders1/90/90/80/9
Infusion site painGeneral disorders1/90/90/80/9
Infusion site swellingGeneral disorders1/90/90/80/9
PyrexiaGeneral disorders1/90/90/80/9
HypoglycaemiaMetabolism and nutrition disorders1/90/90/80/9
HeadacheNervous system disorders0/90/90/81/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin 50 mgSitagliptin 100 mgSitagliptin 200 mgPlaceboTotal
Mean13.9 ± 2.5214.3 ± 1.4114.8 ± 1.7514.1 ± 2.2614.3 ± 1.98
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 50 mgSitagliptin 100 mgSitagliptin 200 mgPlaceboTotal
Female655824
Male343111
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Fraser IP, Neufeld ND, Fox LA, Kipnes MS, Miller TL, Zeitler PS, Rodriguez H, Gilmartin JH, Lee SJ, Patterson JK, Li XS, Maganti L, Luo WL, Tatosian DA, Stoch SA. A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes. Pediatr Diabetes. 2019 Feb;20(1):48-56. doi: 10.1111/pedi.12790. Epub 2018 Nov 13. PubMed 30346099 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2008 to primary completion in Dec 2010, 29 months.

Results were first posted in Jan 2012, 1 year 1 month after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 29 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2008
First posted
Aug 8, 2008
StartActual
Jul 18, 2008
Primary completionActual
Dec 30, 2010
CompletionActual
Feb 14, 2011
Results first posted
Jan 30, 2012
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00730275
Responsible party
Sponsor
First posted
Aug 8, 2008
Start date
Jul 18, 2008
Primary completion
Dec 30, 2010
Completion
Feb 14, 2011
Results posted
Jan 30, 2012
Last update
May 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion